Location: Home
  • search
  • go
  • Relate News
  • 5/14/2019New Report: As Star mAb Drug Patents Expire, Generic Drugs will Shock ...
  • 5/13/2019China to Raise Reimbursement Ratio of Critical Illness Program to 60% ...
  • 5/13/2019NMPA Deepens Regulatory Harmonization with Hong Kong and Macau
  • 5/10/2019Recent Executive Moves
  • 5/10/2019PhRMA Calls for Trade Deals That Force Countries to Pay More for Drugs
  • 5/10/2019Latest Draft of Drug Administration Law Proposes to Ban Platform-based...
  • 5/9/2019NMPA Issues 2018 Food and Drug Regulatory Statistics Annual Report
  • 5/9/2019NHC Minister Outlines Future Healthcare Reform Direction
  • 5/9/2019China Built 158 Internet Hospitals and Telemedicine Platforms in 19 Pr...
  • 5/9/2019Chinese Health Expenditure Projected to Reach 9.1% of GDP by 2035
  • 5/9/2019Chinese Bioethicists Call for 'Reboot' of Biomedical Regulation after ...
  • 5/9/2019Innovent-Lilly Partnership Announces Positive Clinical Results of Ritu...
  • 5/9/2019Helsinn and Mundipharma Launch Cancer Care Drug ALOXI IV in China
  • 5/9/2019Amerigen Announces USFDA Approval for Generic Penicillamine
  • 5/9/2019Alembic Pharma Forms Chinese Joint Venture
  • 5/8/2019Research Point Global and WuXi CDS to Rebrand as WuXi Clinical
  • 5/8/2019Merck's Successful First Quarter Largely Driven by China Growth
  • 5/8/2019NMPA Announces Package Insert Revision of Bromocriptine Mesylate Table...
  • 5/6/2019China's Conditional Approval of Bayer's Acquisition of Monsanto: Lesso...
  • 5/6/2019Sun Pharma Eyes China Expansion with A Local Partner
  • 5/6/2019WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Cli...
  • 5/6/2019Bayer's Pharma Sales in Q1/2019 Benefited from Volume Growth of Some D...
  • 5/5/2019China Pilots Program to Regulate Medical Services by Dynamic Means
  • 5/3/2019Immunomedics and Everest Medicines Announce License Agreement for Saci...
  • 5/3/2019Chinese Hospitals Set to Sell Experimental Cell Therapies
  • 5/3/2019Some Big Pharma Cos Raise 2019 Outlook Driven by China Prospects and N...
  • 5/3/2019Kangmei's $4bn Accounting Error Highlights China Risk
  • 5/1/2019SMEI: Fastest Growing Products in the Top 200 Drugs by Sales Value in ...
  • 4/30/2019Roche's Rituxuan Faces Chinese Biosimilar Challenge from Fosun Pharma
  • 4/30/2019Shanghai Listed Kangmei Pharma Admits to Massive Cash and Revenue Over...
  • Page:118/334 Total number of articles:9998: [First][<<] [116] [117] [118] [119] [120] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group